Derek J Nancarrow
Overview
Explore the profile of Derek J Nancarrow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
534
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ray P, Shukla S, Zhang Y, Donahue K, Nancarrow D, Kasturirangan S, et al.
Mol Cancer Res
. 2025 Feb;
PMID: 39976545
Cooperativity between mutant p53 and mutant KRAS, although recognized, is poorly understood. In pancreatic cancer, mutant p53 induces splicing factor hnRNPK causing isoform switch producing overexpression of GTPase activating protein...
2.
McEwen D, Ray P, Nancarrow D, Wang Z, Kasturirangan S, Abdullah S, et al.
JCI Insight
. 2024 May;
9(13).
PMID: 38781019
Immunosuppression is a common feature of esophageal adenocarcinoma (EAC) and has been linked to poor overall survival (OS). We hypothesized that upstream factors might negatively influence CD3 levels and T...
3.
Kasturirangan S, Nancarrow D, Shah A, Lagisetty K, Lawrence T, Beer D, et al.
Cell Death Dis
. 2024 Mar;
15(3):194.
PMID: 38453895
The advancement of RNAseq and isoform-specific expression platforms has led to the understanding that isoform changes can alter molecular signaling to promote tumorigenesis. An active area in cancer research is...
4.
Hinton T, Karnak D, Tang M, Jiang R, Luo Y, Boonstra P, et al.
Transl Oncol
. 2022 Apr;
21:101428.
PMID: 35460942
Grade 2 and higher radiation pneumonitis (RP2) is a potentially fatal toxicity that limits efficacy of radiation therapy (RT). We wished to identify a combined biomarker signature of circulating miRNAs...
5.
Ray P, Nancarrow D, Ferrer-Torres D, Wang Z, Martinho M, Hinton T, et al.
Cell Mol Gastroenterol Hepatol
. 2021 Aug;
13(1):129-149.
PMID: 34416429
Background & Aims: TP53 mutations underlie Barrett's esophagus (BE) progression to dysplasia and cancer. During BE progression, the ubiquitin ligase (E3) RNF128/GRAIL switches expression from isoform 2 (Iso2) to Iso1,...
6.
Lagisetty K, McEwen D, Nancarrow D, Schiebel J, Ferrer-Torres D, Ray D, et al.
JCI Insight
. 2020 Dec;
6(1).
PMID: 33290281
Esophageal adenocarcinoma (EAC) develops from Barrett's esophagus (BE), a chronic inflammatory state that can progress through a series of transformative dysplastic states before tumor development. While molecular and genetic changes...
7.
Martinho M, Nancarrow D, Lawrence T, Beer D, Ray D
Cell Mol Gastroenterol Hepatol
. 2020 Nov;
11(2):449-464.
PMID: 33130332
The incidence of esophageal adenocarcinoma (EAC) and other gastrointestinal (GI) cancers have risen dramatically, thus defining the oncogenic drivers to develop effective therapies are necessary. Patients with Barrett's Esophagus (BE),...
8.
Ma X, Kang X, He L, Zhou J, Zhou J, Sturm M, et al.
Mol Pharm
. 2019 Jul;
16(8):3726.
PMID: 31310132
No abstract available.
9.
Ma X, Kang X, He L, Zhou J, Zhou J, Sturm M, et al.
Mol Pharm
. 2019 Apr;
16(5):2199-2213.
PMID: 30974945
Tumor targeting agents are being developed for early tumor detection and therapeutics. We previously identified the peptide SNFYMPL (SNF*) and demonstrated its specific binding to human esophageal specimens of high-grade...
10.
Ferrer-Torres D, Nancarrow D, Steinberg H, Wang Z, Kuick R, Weh K, et al.
Gastroenterology
. 2018 Dec;
156(5):1404-1415.
PMID: 30578782
Background & Aims: African American and European American individuals have a similar prevalence of gastroesophageal reflux disease (GERD), yet esophageal adenocarcinoma (EAC) disproportionately affects European American individuals. We investigated whether...